Navigation Links
ACE Inhibitors Seem to Raise Risk of Breast Cancer Recurrence
Date:4/22/2011

By Amanda Gardner
HealthDay Reporter

THURSDAY, April 21 (HealthDay News) -- Two commonly used blood pressure medications seem to have opposite effects on the chances of breast cancer recurring in women with a personal history of the disease.

Preliminary findings show that ACE inhibitors increased the risk of recurrence, which surprised even the researchers, who published their study online in the journal Breast Cancer Research and Treatment.

On the other hand, beta blockers seemed to reduce the risk, which is in keeping with prior studies on the subject.

Fortunately, when the two drugs were combined, beta blockers seemed to mitigate the increased risk of recurrence linked with ACE inhibitors.

The study reflects the increasing interest among scientists in the effect the "microenvironment" -- which can include chronically used medications in addition to alcohol, tobacco and physical activity -- might have on the course of a particular woman's breast cancer.

"Tumors may be living in the breast before we even known about it. The microenvironment may either facilitate or keep under control whether the cells disseminate," said study first author Dr. Patricia A. Ganz, director of cancer prevention and control research at the Jonsson Comprehensive Cancer Center at University of California Los Angeles.

The study suggested that certain medications used to treat heart disease and high blood pressure might have an adverse effect on breast cancer survivors, she and the other researchers noted.

A 2010 study by Jonsson Comprehensive Cancer Center researchers on mice had already looked at beta blockers and cancer spread (or metastasis). That study began by documenting that stress can affect how fast and how widely a tumor spreads in rodents. The mice were confined in a small tube for a couple of hours a day, and the resulting stress prompted immune cells to gather in the tumor cells, enabling quicker metastasis and a 30-fold increase in cancer spread, deeper analysis revealed.

But in this animal model, beta blockers managed to block the signals that were recruiting the immune cells, explained Ganz.

That same year, a study of more than 400 women in England and Germany found that women on beta blockers also had a lower likelihood of breast cancer recurrence.

The UCLA researchers decided to delve deeper, working with other scientists on a database of 1,779 women with early-stage breast cancer who had been treated at a large health maintenance organization in northern California and followed for about eight years in a study called Life After Cancer Epidemiology (LACE).

The women in the group who were taking ACE inhibitors had a 56 percent increased risk of a recurrence, although they had no increased risk of death.

The 14 percent of women who were taking propanolol -- the beta blocker considered most likely to have a protective effect -- had a reduced risk of recurrence. Because the number of women in this group was so small, the findings did not reach statistical significance, Ganz said, although "it was going in the right direction in terms of being protective."

The risk associated with taking both drugs together was somewhat in the middle.

The study was funded by the Jonsson Comprehensive Cancer Center Foundation, the Breast Cancer Research Foundation and the U.S. National Cancer Institute.

Noting the need for further studies, Ganz is working with researchers in Denmark and Canada to evaluate the same medications and their relationship to recurrence in much larger samples of breast cancer patients.

"We've always been addressing the treatment of the cancer itself but in this study [they were looking at whether] there is something in the host, in the milieu that makes us more susceptible to the development of a malignancy. Is there something we can actually change?" said Dr. Lauren Cassell, chief of breast surgery at Lenox Hill Hospital in New York City.

Still, the research is very preliminary. "People have to realize this is just a work-in-progress and shouldn't stop their medicines if they happen to be on one of these medications," said Dr. Nieca Goldberg, director of the Women's Heart Program at NYU Langone Medical Center in New York City.

"If they are concerned because they have breast cancer or they're at high risk for breast cancer," Goldberg said, "they should really express this to their doctors because there are other options for medicines."

More information

The U.S. National Cancer Institute has more on breast cancer.

SOURCES: Patricia A. Ganz, M.D., director, cancer prevention and control research, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Nieca Goldberg, M.D., director, Women's Heart Program, NYU Langone Medical Center, New York City; Lauren Cassell, M.D., chief of breast surgery, Lenox Hill Hospital, New York City; April 10, 2011, Breast Cancer Research and Treatment, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. ACE inhibitors may increase risk of recurrence in breast cancer survivors
2. Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity
3. Combining 2 peptide inhibitors might block tumor growth
4. Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate
5. JAK inhibitors producing significant response in myelofibrosis patients
6. Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
7. Birth Even a Few Weeks Early May Raise Odds for ADHD
8. Low Glucose Levels May Raise Death Risk Among Older People
9. NIDA raises the curtain on addiction
10. Having Both Autism and Epilepsy Linked to Raised Death Rates
11. Close-Knit Neighborhoods Raise Chances of Stroke Survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ACE Inhibitors Seem to Raise Risk of Breast Cancer Recurrence
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology: